SVB Leerink Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)

SVB Leerink began coverage on shares of Trevi Therapeutics (NASDAQ:TRVIGet Rating) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $6.00 target price on the stock. SVB Leerink also issued estimates for Trevi Therapeutics’ Q4 2022 earnings at ($0.08) EPS, FY2022 earnings at ($0.49) EPS, FY2023 earnings at ($0.41) EPS, FY2024 earnings at ($0.59) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($1.17) EPS.

Several other analysts also recently commented on TRVI. Oppenheimer dropped their price objective on Trevi Therapeutics to $9.00 in a research note on Thursday, November 17th. Needham & Company LLC cut their price objective on Trevi Therapeutics from $10.00 to $8.00 and set a buy rating on the stock in a report on Friday, November 11th.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $1.82 on Tuesday. The stock has a market cap of $109.05 million, a PE ratio of -2.33 and a beta of 0.75. The stock has a 50-day moving average of $1.96 and a 200-day moving average of $2.63. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.70 and a quick ratio of 8.70. Trevi Therapeutics has a one year low of $0.46 and a one year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVIGet Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. As a group, sell-side analysts expect that Trevi Therapeutics will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors have recently added to or reduced their stakes in TRVI. Commonwealth Equity Services LLC bought a new stake in shares of Trevi Therapeutics in the first quarter valued at about $33,000. Virtu Financial LLC bought a new stake in Trevi Therapeutics in the 1st quarter valued at approximately $44,000. Acuta Capital Partners LLC acquired a new position in Trevi Therapeutics during the 2nd quarter worth approximately $98,000. State Street Corp bought a new position in shares of Trevi Therapeutics during the 1st quarter worth approximately $81,000. Finally, Jump Financial LLC acquired a new stake in shares of Trevi Therapeutics in the third quarter valued at approximately $66,000.

Trevi Therapeutics Company Profile

(Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Recommended Stories

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.